HCPCS Level IIdrugActive
J0752
Hiv prep, oral lenacapavir
BETOS: O1E
Effective: 2025-10-01
Referenced in 1 policies
Description
Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Yeztugo
Manufacturer
Gilead Sciences, Inc.
HCPCS Dosage
300 MG
Billing Units
4.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.